Avanir Pharmaceuticals

Neurodex developer reports loss of $0.30 per share

Published in Mental Health Business Week, January 7th, 2006

Avanir Pharmaceuticals (AVN) reported unaudited financial results for the quarter and fiscal year ended September 30, 2005.

For the fiscal year ended September 30, 2005, Avanir's net loss was $30.6 million, or $0.30 per share, compared to a net loss of $28.2 million, or $0.36 per share, for the fiscal year ended September 30, 2004.

Total revenues for fiscal 2005 increased to $16.7 million, compared to $3.6 million in fiscal 2004. The increase in revenues is primarily due to licensed technology and research and development services being provided in fiscal 2005 in connection with two new license agreements with AstraZeneca U.K. Limited and Novartis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Business Week

Source: Mental Health Business Week (2006-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry